Novel selective cannabinoid CB1 receptor antagonist MJ08 with potent in vivo bioactivity and inverse agonistic effects

[1] Xie S(2007)The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB J Clin Pharm Ther 32 209-31

[2] Furjanic MA(2009) receptor antagonism — or inverse agonism — as potential obesity treatment and other therapeutic use Expert Opin Emerg Drugs 14 43-65

[3] Ferrara JJ(2009)Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis Br J Pharmacol 156 397-411

[4] McAndrew NR(2008)Emerging strategies for exploiting cannabinoid receptor agonists as medicines Br J Pharmacol 154 915-7

[5] Ardino EL(2009)Rimonabant in rats with a metabolic syndrome: good news after the depression Best Pract Res Clin Endocrinol Metab 23 103-16

[6] Ngondara A(2004)Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders Pharmacol Res 50 453-69

[7] Janero DR(2009)Emerging aspects of pharmacotherapy for obesity and metabolic syndrome Curr Top Med Chem 9 482-503

[8] Makriyannis A(2010)The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents Bioorg Med Chem Lett 20 453-7

[9] Pertwee RG(2005)Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier Life Sci 76 1307-24

[10] Di Marzo V(2009)Inverse agonism and neutral antagonism at cannabinoid CB1 receptors Int J Obes (Lond) 33 947-55

[1] Xie S(2007)The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB J Clin Pharm Ther 32 209-31

[2] Furjanic MA(2009) receptor antagonism — or inverse agonism — as potential obesity treatment and other therapeutic use Expert Opin Emerg Drugs 14 43-65

[3] Ferrara JJ(2009)Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis Br J Pharmacol 156 397-411

[4] McAndrew NR(2008)Emerging strategies for exploiting cannabinoid receptor agonists as medicines Br J Pharmacol 154 915-7

[5] Ardino EL(2009)Rimonabant in rats with a metabolic syndrome: good news after the depression Best Pract Res Clin Endocrinol Metab 23 103-16

[6] Ngondara A(2004)Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders Pharmacol Res 50 453-69

[7] Janero DR(2009)Emerging aspects of pharmacotherapy for obesity and metabolic syndrome Curr Top Med Chem 9 482-503

[8] Makriyannis A(2010)The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents Bioorg Med Chem Lett 20 453-7

[9] Pertwee RG(2005)Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier Life Sci 76 1307-24

[10] Di Marzo V(2009)Inverse agonism and neutral antagonism at cannabinoid CB1 receptors Int J Obes (Lond) 33 947-55